[go: up one dir, main page]

PE20011163A1 - TREATMENT OF KIDNEY DISORDERS - Google Patents

TREATMENT OF KIDNEY DISORDERS

Info

Publication number
PE20011163A1
PE20011163A1 PE2001000305A PE2001000305A PE20011163A1 PE 20011163 A1 PE20011163 A1 PE 20011163A1 PE 2001000305 A PE2001000305 A PE 2001000305A PE 2001000305 A PE2001000305 A PE 2001000305A PE 20011163 A1 PE20011163 A1 PE 20011163A1
Authority
PE
Peru
Prior art keywords
treatment
kidney disorders
agent
dihydropyridine
endothelin
Prior art date
Application number
PE2001000305A
Other languages
Spanish (es)
Inventor
Adrian Paul Foster
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20011163A1 publication Critical patent/PE20011163A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE UN BLOQUEANTE DE LOS CANALES DE CALCIO TAL COMO DIHIDROPIRIDINA, BESILATO DE AMLODIPINO UTILIZANDO DE 0,1 mg A 1,5mg; OPCIONALMENTE EN PRESENCIA DE UN AGENTE ANTIHIPERTENSIVO DE UNA CLASE DIFERENTE TAL COMO UN AGENTE QUE REDUCE EL EFECTO DE LA ENDOTELINA, ANGIOTENSINA; PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA INSUFICIENCIA RENAL CRONICA EN ANIMALES NORMOTENSOSREFERS TO THE USE OF A CALCIUM CHANNEL BLOCKER SUCH AS DIHYDROPYRIDINE, AMLODIPINE BESYLATE USING 0.1 mg TO 1.5 mg; OPTIONALLY IN THE PRESENCE OF AN ANTIHYPERTENSIVE AGENT OF A DIFFERENT CLASS SUCH AS AN AGENT THAT REDUCES THE EFFECT OF ENDOTHELIN, ANGIOTENSIN; FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC KIDNEY INSUFFICIENCY IN NORMOTENSIVE ANIMALS

PE2001000305A 2000-04-04 2001-04-02 TREATMENT OF KIDNEY DISORDERS PE20011163A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament

Publications (1)

Publication Number Publication Date
PE20011163A1 true PE20011163A1 (en) 2001-11-12

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000305A PE20011163A1 (en) 2000-04-04 2001-04-02 TREATMENT OF KIDNEY DISORDERS

Country Status (12)

Country Link
EP (1) EP1284719A2 (en)
JP (1) JP2003528927A (en)
AR (1) AR027763A1 (en)
AU (1) AU2001239510A1 (en)
BR (1) BR0109783A (en)
CA (1) CA2403950A1 (en)
GB (1) GB0008332D0 (en)
MX (1) MXPA02009819A (en)
PA (1) PA8514601A1 (en)
PE (1) PE20011163A1 (en)
TN (1) TNSN01051A1 (en)
WO (1) WO2001074390A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AU2001294354A1 (en) * 2000-12-29 2002-07-16 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
AT5874U1 (en) * 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
NL1021822C2 (en) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosin tablets.
NL1019882C2 (en) * 2002-02-01 2003-08-04 Synthon Licensing Pharmaceutical tablet composition useful for treating or preventing hypertension, angina or congestive heart failure comprises amlodipine free base
CO5400144A1 (en) * 2002-03-11 2004-05-31 Novartis Ag ORGANIC COMPOUNDS
EP1551456A4 (en) * 2002-09-30 2007-08-22 Kowa Co PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
PL377344A1 (en) 2003-01-31 2006-01-23 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
NZ561486A (en) 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
WO2006119049A2 (en) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methods for prolonging feline life
KR20180123021A (en) * 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 Medicines for the treatment of kidney disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
DK0459666T3 (en) * 1990-05-31 1994-12-05 Pfizer Medicines for impotence
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
EP1262182A3 (en) * 1991-11-26 2003-02-26 Sepracor Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine
US6245787B1 (en) * 1995-03-16 2001-06-12 Pfizer Inc. Composition containing amlodipine or a pharmaceutically acceptable salt thereof, and an ACE inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
CA2403950A1 (en) 2001-10-11
GB0008332D0 (en) 2000-05-24
WO2001074390A2 (en) 2001-10-11
TNSN01051A1 (en) 2005-11-10
PA8514601A1 (en) 2002-08-26
EP1284719A2 (en) 2003-02-26
BR0109783A (en) 2003-01-21
JP2003528927A (en) 2003-09-30
WO2001074390A3 (en) 2002-05-30
MXPA02009819A (en) 2003-03-27
AR027763A1 (en) 2003-04-09
AU2001239510A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
AR028423A1 (en) HIV REPLICATION INHIBITORS
NL300343I2 (en) 6-alpha, 9-alpha-difluoro-17-alpha (2-furanylcarboxyl) oxy-11-beta-hydroxy-16-alpha-methyl-3-oxo-androst-1,4-diene-17-carbothionic acid -fluoromethyl ester as an anti-inflammatory agent
SI3808743T1 (en) Pyrimidines that inhibit HIV replication
AR021981A1 (en) PHARMACEUTICAL COMPOSITION FOR AN ORAL ROUTE ADMINISTRATION TO AVOID THE DEVIATION OF USE THROUGH A THIRD PARTY
PE20011163A1 (en) TREATMENT OF KIDNEY DISORDERS
FR2804025B1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS
CY2007031I1 (en) SUSTAINED RELEASE ORAL DOSAGE COMPOSITION
DE60028536D1 (en) In the oral cavity rapidly disintegrating oral solid administration form
DK1600154T3 (en) Extended release osmotic dosage form
EE05104B1 (en) Azetidine derivatives, methods for their preparation and pharmaceutical composition
IS6686A (en) Hydrogel-powered dosage form
AU3652102A (en) Compounds and their uses
ATE289640T1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANES
EE200100293A (en) Controlled release dosage form containing GnRH-II
BG66093B1 (en) Controlled release compositions comprising nimesulide
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
ATE355271T1 (en) PHARMACEUTICAL COMPOSITION
DE60143363D1 (en) PHARMACEUTICAL COMPOSITIONS THAT PROMOTE THE IMMUNOGENICITY OF WEAK IMMUNOGENIC ANTIGENES
ATE252377T1 (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING TILIDINE MESYLATE AS THE ACTIVE INGREDIENT
IT1302682B1 (en) ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORPHINE
PL376130A1 (en) Controlled releases system containing temozolomide
NO20023976L (en) Endoparasitic compositions
IS6690A (en) Tricyclic 2-pyridone compounds, useful as HIV crossover inhibitors
NO20040857L (en) New oral prolonged release dosage form.
CR8948A (en) PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
FC Refusal